Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition
Following publication of the original article [1], an error was noted in the GAPDH in the western blot depicted in Figure 4b.
Main Authors: | Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, James W. Hodge |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-09-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0715-9 |
Similar Items
-
Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
by: Kathleen E. Fenerty, et al.
Published: (2018-11-01) -
The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas
by: Nazanin Majd, et al.
Published: (2020-11-01) -
Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function
by: Jiajia Li, et al.
Published: (2023-01-01) -
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
by: Stephen A. Jannetti, et al.
Published: (2020-03-01) -
Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
by: Chia-Hao Liu, et al.
Published: (2017-10-01)